Hamilton, Ontario, October 3, 2018 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, today is announcing that its founder, Dr. John Valliant, has stepped down from his role as CEO to focus his time as the CEO of Fusion Pharmaceuticals. Dr. Valliant will maintain his role as the Principal Investigator on CPDC’s grants and as a member of CPDC’s Board of Directors, providing support to management and to McMaster University as CPDC’s host institution. CPDC has appointed Dr. Joe McCann, CPDC’s current Chief Operating Officer, as its new CEO and President, effective immediately.
“It has been an honour to work with so many great partners over the past 10 years and to watch CPDC continue to grow and deliver value to patients, our stakeholders and employees,” stated Dr. Valliant. “I am fortunate that I will continue to be associated with such an important organization and will continue working with CPDC’s Board of Directors and the talented management team led by new CEO Dr. Joe McCann.”
Dr. Robert Sutherland, Chair of CPDC, said in a statement: “We would like to thank John for his significant contributions to CPDC over the last 10 years, and we look forward to John continuing to shape the vision of CPDC as its Principal Investigator and as a Board Member. John has built a strong management team with the experience, expertise and track record of success that will lead CPDC well into the future as it works to deliver on new initiatives that will position Canada at the forefront of the rapidly growing radiopharmaceutical sector. We are delighted to welcome Joe McCann as CPDC’s new CEO. His expertise, knowhow and knowledge in the radiopharmaceutical space are an excellent fit to deliver on CPDC’s commitments to advancing imaging research and delivering on new initiatives in medical isotopes.”
Dr. McCann joined CPDC in 2010. He has held roles of increasing responsibility over this time and has made significant contributions toward CPDC’s success of the last eight years, including
playing a key role in CPDC receiving a record third round of funding from the Centres of Excellence for Commercialization and Research (CECR), with support from numerous industry and academic partners. The CECR program is part of the Networks of Centres of Excellence of Canada program (NCE).
Dr. McCann commented: “I am honoured to be named CPDC’s CEO and President, and I would like to thank John, Bob and my colleagues for the support and mentorship they provided over the years that prepared me for this role. The radiopharmaceutical space is expanding rapidly and our third round of CECR program funding, and continued support from The Ontario Institute for Cancer Research (OICR) and McMaster University, positions us well to stay at the forefront of the industry and deliver on our commitments to stakeholders and the research community in Ontario and Canada.”
The Centre for Probe Development and Commercialization (CPDC) is a Centre of Excellence for Commercialization and Research (CECR) located at McMaster University in Hamilton, Ontario, Canada. CPDC is a private, not-for-profit company and global leader in the discovery, development and commercialization of next-generation radiopharmaceuticals that was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and The Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a pipeline of products along with a robust and reliable global supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. For more information about CPDC, please visit: www.imagingprobes.ca.
Centre for Probe Development and Commercialization
Angela Laurentani, 905 525-9140, ext. 21212
LONDON, Ontario – Led by researchers at Lawson Health Research Institute, a multi-centre registry trial is testing the use of a new imaging tracer, called a PSMA tracer, for early detection of recurrent prostate cancer. The registry gives patients access to a new type of imaging and will assess the impact on patient care. PSMA
VANCOUVER, British Columbia–ARTMS Products Inc., the global leader in the innovation and commercialization of novel technologies that enable cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce the appointment of Charles S. Conroy R.Ph, MBA as its Chief Executive Officer. Mr. Conroy brings to ARTMS more than 25 years of experience
VANCOUVER, British Columbia–ARTMS Products Inc., a global leader in the development and commercialization of novel technologies and products that enable cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce they have received $1.5 million funding from Western Economic Diversification Canada as part of its Business Scale-up and Productivity program. The federal